Pharmacists' participation in an inhaled respiratory medication program: Reimbursement of professional fees

Annals of Pharmacotherapy

Volumn 39, Issue 4, 2005, Pages 655-661

  Murphy, Andrea L ^a   MacKinnon, Neil J ^a   Flanagan, Priti S ^b,c   Bowles, Susan K ^a,d   Sketris, Ingrid S ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

^b DALHOUSIE UNIVERSITY   (Canada)

^c FRASER HEALTH AUTHORITY   (Canada)

^d Centre for Health Care of the Elderly   (Canada)

Author keywords

Cognitive services; Inhaled respiratory medications; Reimbursement

Indexed keywords

ADULT; AGED; ARTICLE; ARTIFICIAL VENTILATION; AWARENESS; CANADA; CLINICAL PRACTICE; COMMUNITY CARE; CONTROLLED STUDY; CORRELATION ANALYSIS; DEMOGRAPHY; DEVICE; FEE; FEMALE; FOLLOW UP; HEALTH CARE MANAGEMENT; HEALTH EDUCATION; HEALTH PROGRAM; HEALTH SURVEY; HOSPITAL BILLING; HUMAN; INFORMATION PROCESSING; MALE; MULTIVARIATE ANALYSIS; PERCEPTION; PHARMACIST; PRIORITY JOURNAL; PROFESSIONAL PRACTICE; PUBLIC HEALTH INSURANCE; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; REIMBURSEMENT; SELF REPORT; SEX DIFFERENCE; STANDARDIZATION; STATISTICAL SIGNIFICANCE; TECHNIQUE;

ADMINISTRATION, INHALATION; ADULT; COMMUNITY PHARMACY SERVICES; FEE-FOR-SERVICE PLANS; FEES, PHARMACEUTICAL; FEMALE; HUMANS; MALE; MIDDLE AGED; NOVA SCOTIA; PATIENT EDUCATION; PHARMACISTS; PRESCRIPTIONS, DRUG; RESPIRATORY THERAPY;

EID: 15444379560     PISSN: 10600280     EISSN: None     Source Type: Journal    
DOI: 10.1345/aph.1E286     Document Type: Article

References (26)

1. Helper CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm 1990;47:533-43.
2. Smith DH, Fassett WE, Christensen DB. Washington State CARE project: downstream cost changes associated with the provision of cognitive services by pharmacists. J Am Pharm Assoc 1999;39:650-7.
3. Schumock GT, Butler MG, Meek PD, Vermeulen LC, Arondekar BV, Bauman JL. Evidence of the economic benefit of clinical pharmacy services: 1996-2000. Pharmacotherapy 2003;23:113-32.
4. Cranor CW, Christensen DB. The Asheville Project: factors associated with outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:160-72.
5. Cranor CW, Christensen DB. The Asheville Project: long-term clinical and economic outcomes of a community pharmacy diabetes care program. J Am Pharm Assoc 2003;43:173-84.
6. Amsler MR, Murray MD, Tierney WM, Brewer N, Harris LE, Marrero DG. Pharmaceutical care in chain pharmacies: beliefs and attitudes of pharmacists and patients. J Am Pharm Assoc 2001;41:850-5.
7. Christensen DB, Hansen RW. Characteristics of pharmacies and pharmacists associated with the provision of cognitive services in the community setting. J Am Pharm Assoc 1999;39:640-9.
8. Miller MJ, Ortmeier BG. Factors influencing the delivery of pharmacy services. Am Pharm 1995;NS35:39-45.
9. Raisch DW Patient counseling in community pharmacy and its relationship with prescription payment methods and practice settings. Ann Pharmacother 1993;27:1173-9.
10. Bachynysky J, Dabisza S, Sullivan K, Guirguis M. Cognitive services. Pharmacist valuation of service fees. Can Pharm J 1997;130:26-31.
11. Kröger E, Moisan J, Grégoire J-P. Billing for cognitive services: understanding Québec pharmacists' behavior. Ann Pharmacother 2000;34:309-16. DOI 10.1345/aph.19133
12. Poirer S, Buffington DE, Memoli GA. Billing third party payers for pharmaceutical care services. J Am Pharm Assoc 1999;39:50-64.
13. Lemiere C, Bai T, Balter M, Bayliff C, Becker A, Boulet LP, et al. Adult asthma consensus guidelines update 2003. Can Respir J 2004;11(suppl A):9A-18A.
14. O'Donnell DE, Aaron S, Bourbeau J, Hernandez P, Marciniuk D, Balter M, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2003. Can Respir J 2003;10(suppl A):11A-33A.
15. National Asthma Education and Prevention Program Expert Panel. Guidelines for the diagnosis and management of asthma: update on selected topics. J Allergy Clin Immunol 2002;110(suppl 5):S141-218.
16. National Collaborating Centre for Chronic Conditions. Chronic obstructive pulmonary disease: national clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(suppl 1):1-232. DOI 10.1136/thx.2004.022707
17. Turner MO, Patel A, Ginsberg S, Fitzgerald JM. Bronchodilator delivery in acute airflow obstruction: a meta-analysis. Arch Intern Med 1997;157:1736-44.
18. Cates CJ, Bara A, Crilly JA, Rowe BH. Holding chambers versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database of Systematic Reviews 2003(2):CD000052. DOI 10.1002/14651858.CD000052
19. Sketris I, McLean-Veysey P. A provincial program in Nova Scotia to decrease the use of wet nebulization respiratory medications. J Managed Care Pharm 2000;6:457-62.
20. Drug Evaluation Alliance of Nova Scotia: Inhalation therapy. In: Wedlake S, ed. President's bulletin. Halifax: Nova Scotia Pharmaceutical Society, March 2000.
21. AeroChamber and AeroChamberPlus Valved Holding Chamber. London, Canada: Trudell Medical International, London, Canada, www.trudellmed.com/index.shtml (accessed 2004 Mar 21).
22. McDermott JH, Christensen DB. Provision of pharmaceutical care services in North Carolina: a 1999 survey. J Am Pharm Assoc 2002;42:26-35.
23. Dillman DA. Mail and telephone surveys: the total design method. Toronto: Wiley, 1978.
24. Salant P, Dillman DA. How to conduct your own survey. New York: Wiley, 1994.
25. Poirer S. Reimbursement for cognitive services: Québec's experience. Am Pharm 1992;NS32:56-60.
26. 2004 Nova Scotia Wage and Benefit Survey results. The Pharmacist. Pharmacy Association of Nova Scotia. 2004 May;6(5).